These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 28807236)

  • 1. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.
    Zeidan AM; Pullarkat VA; Komrokji RS
    Crit Rev Oncol Hematol; 2017 Sep; 117():57-66. PubMed ID: 28807236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To chelate or not to chelate in MDS: That is the question!
    Zeidan AM; Griffiths EA
    Blood Rev; 2018 Sep; 32(5):368-377. PubMed ID: 29602612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
    Leitch HA; Vickars LM
    Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron chelation therapy in myelodysplastic syndromes: where do we stand?
    Mitchell M; Gore SD; Zeidan AM
    Expert Rev Hematol; 2013 Aug; 6(4):397-410. PubMed ID: 23991926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
    Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
    Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?
    Gattermann N
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):465-473. PubMed ID: 32089223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
    Wong CAC; Wong SAY; Leitch HA
    Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
    Leitch HA; Gattermann N
    Crit Rev Oncol Hematol; 2019 Sep; 141():54-72. PubMed ID: 31228649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
    Imran F; Phatak P
    Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
    Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
    Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
    Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
    Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
    Shammo JM; Komrokji RS
    Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement.
    Ko BS; Chang CS; Chang MC; Chen TY; Chiou TJ; Chiu CF; Huang WL; Kao WY; Lan YJ; Lin SF; Tan TD; Tang JL; Tzeng CH; Wang PN; Yet SP; Tien HF
    Int J Hematol; 2014 Jul; 100(1):7-15. PubMed ID: 24924953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes.
    Carreau N; Tremblay D; Savona M; Kremyanskaya M; Mascarenhas J
    Blood Rev; 2016 Sep; 30(5):349-56. PubMed ID: 27106071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron overload in patients with myelodysplastic syndromes.
    Jensen PD
    Curr Hematol Malig Rep; 2007 Feb; 2(1):13-21. PubMed ID: 20425384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron overload in myelodysplastic syndromes: diagnosis and management.
    List AF
    Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis.
    Liu H; Yang N; Meng S; Zhang Y; Zhang H; Zhang W
    Clin Exp Med; 2020 Feb; 20(1):1-9. PubMed ID: 31712933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controversies surrounding iron chelation therapy for MDS.
    Leitch HA
    Blood Rev; 2011 Jan; 25(1):17-31. PubMed ID: 21030120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
    Leitch HA
    Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.